Shire flu vaccine
Executive Summary
Shire Fluviral flu vaccine will enter Phase III trials to support applications in U.S. and Europe in mid-2002. The company plans to increase annual production capacity from 8 mil. doses to 25 mil. doses over the next five years to serve the two markets. Although Fluviral presently uses thimerosal as a preservative, Shire is working on reformulating a thimerosal-free version of the flu vaccine...